Halotestin (Fluoxymesterone): Extreme Androgenicity Research

Research Disclaimer: Fluoxymesterone is sold exclusively for in-vitro and laboratory research use. Not for unsupervised use. This content does not constitute medical advice.

Fluoxymesterone (17α-methyl-9α-fluoro-11β-hydroxy-testosterone; Halotestin, Ultandren) is the most androgenic orally active androgen studied, with an A:A ratio of approximately 1900:1 in the Hershberger assay and an AR affinity approximately 8× that of testosterone. Its extreme potency results from a unique combination of modifications: the 9α-fluoro group increases both AR affinity (by electron withdrawal effects on ring B) and resistance to aromatization, while the 11β-hydroxy group confers partial glucocorticoid receptor (GR) activity. Originally developed for aplastic anemia and breast cancer, fluoxymesterone is pharmacologically distinctive as a research tool for studying extreme androgenicity, aggressive behavior circuits, and the structural chemistry of fluorinated steroids.

Table of Contents#

1. Structure: 9α-Fluoro and 11β-Hydroxy Chemistry
2. AR Binding: Extreme Affinity Mechanism
3. Why Fluoxymesterone Doesn't Aromatize
4. GR Activity: 11β-Hydroxy Contribution
5. Aggression and CNS Androgenicity Research
6. Erythropoiesis and Anemia Research
7. Hepatotoxicity Profile
8. Research Protocols
9. Key References

Structure: 9α-Fluoro and 11β-Hydroxy Chemistry#

Fluoxymesterone modifications from testosterone:

1. C17α-methyl (standard oral bioavailability):

• Same as stanozolol, oxymetholone, methandrostenolone
• Blocks 17β-HSD → oral bioavailability ~80%

2. 9α-Fluoro substitution:

• Fluorine at C9α position (on ring B/C junction)
• 9α-F is a strong electron-withdrawing substituent
• Effect on AR binding: electron withdrawal → changes ring B electron density → alters hydrophobic interactions with AR LBD → substantially increased AR affinity
• Effect on 5α-reductase: 9α-F blocks 5α-reductase conversion → no DHT equivalent
• Effect on aromatization: aromatase cannot act on 9α-fluoro ring B/A system

3. 11β-Hydroxy group:

• Hydroxyl at C11β position
• This is the same C11 position present in cortisol (11β-hydroxy) and corticosterone
• Confers partial glucocorticoid receptor (GR) binding affinity
• Makes fluoxymesterone uniquely BOTH an AR agonist AND partial GR agonist/antagonist

Combined effect: These three modifications produce a compound with extreme AR potency, zero aromatization, partial GR activity, and no 5α-reductase substrate recognition — a unique pharmacological profile.

AR Binding: Extreme Affinity Mechanism#

AR affinity:

• Fluoxymesterone relative binding affinity: ~800–1900% of testosterone (depending on assay)
• This is the highest AR affinity of any clinically used androgen
• Comparison: DHT ~300% of T; trenbolone ~500% of T; fluoxymesterone ~800–1900% of T

A:A ratio:

• Hershberger: ~1900:1 (levator ani / ventral prostate, castrated rat)
• This is 20-fold higher than testosterone and represents the theoretical maximum for anabolic-to-androgenic ratio in the original steroid class before SARMs

Mechanism of high AR affinity:

• 9α-Fluoro electron withdrawal → changes ring B electron density → enhanced van der Waals and hydrophobic contacts with AR LBD Leu-704, Phe-764, Met-780 residues
• 11β-OH → additional hydrogen bond to AR Asn-705 (hypothesized)
• Slow koff from AR LBD: longer nuclear AR residence → prolonged target gene transcription

Why Fluoxymesterone Doesn't Aromatize#

Normal aromatization mechanism (testosterone):

• Aromatase acts on ring A (C1–C4 region) via sequential hydroxylations
• Requires accessible C4 and C1,2 hydrogen atoms for the enolization step

Fluoxymesterone aromatase resistance:

• 9α-F on ring B → significant electronic effects propagate through ring B/A junction
• Alters the geometry and electronic accessibility of ring A for aromatase
• Additionally, the fluorine at C9 changes the C10,11 bond angle → affects C4 accessibility
• No detectable estradiol metabolites from fluoxymesterone in vivo

Unlike 4-chloro (turinabol) mechanism:

• Turinabol: C4-Cl physically blocks aromatase at ring A
• Fluoxymesterone: 9α-F blocks aromatase via electronic/conformational effects through ring B

Both are structural mechanisms for aromatization prevention, but different positions and mechanisms — pharmacologically distinct for aromatase binding/mechanism research.

GR Activity: 11β-Hydroxy Contribution#

11β-Hydroxy steroids and the GR:

• Glucocorticoids (cortisol, corticosterone) possess 11β-OH → this is the key hydrogen bond donor for GR binding
• Fluoxymesterone's 11β-OH confers partial GR affinity

Measured GR affinity:

• Fluoxymesterone GR RBA: ~50–80% of dexamethasone (a full GR agonist)
• Much higher GR affinity than standard androgens (testosterone GR RBA ~2%)
• Trenbolone also has significant GR activity (~30–40% dexamethasone); fluoxymesterone's is higher

GR functional activity:

• Cell assays (GR-transfected cells + GRE-reporter): fluoxymesterone → partial GR agonism in the absence of glucocorticoids; partial GR antagonism in the presence of cortisol/dexamethasone
• Tissue-specific outcome: liver → GR agonist effects (glucose, gluconeogenesis); muscle → GR antagonist effects (anti-catabolic)

Research implication: Fluoxymesterone is a dual AR/GR pharmacological tool. The contribution of GR activity to its pharmacological profile (anabolic and behavioral) is not fully separated from AR effects and represents an active research question.

Aggression and CNS Androgenicity Research#

The behavioral profile:

• Fluoxymesterone is consistently reported to produce more aggressive behavior per unit anabolic effect than other androgens
• Animal models: fluoxymesterone → higher resident-intruder aggression scores than testosterone at equivalent AR-occupancy doses
• Human case literature: strong association with aggression/irritability (user reports + clinical records)

Mechanism theories:

1. AR activation in amygdala and hypothalamus: AR-rich areas of CNS; extreme AR potency → higher CNS AR activation per dose
2. GR partial agonism in prefrontal cortex: alters cortisol-GR feedback in emotional regulation circuits
3. GABA modulation: androgens → neurosteroid pathway (via 3α-HSD in brain → 5α-reduced metabolites → GABA-A modulation); fluoxymesterone's 9α-F/11β-OH may alter this pathway
4. Serotonin system modulation: androgens → 5-HT2A receptor expression changes in limbic system; high AR occupancy → altered serotonergic tone

Research design consideration: Separating AR vs. GR contribution to fluoxymesterone's aggression effects requires GR-selective blockade (mifepristone for GR) + AR blockade (flutamide) in a factorial design.

Erythropoiesis and Anemia Research#

Erythropoietic potency:

• Fluoxymesterone: one of the most potent erythropoiesis-stimulating androgens per mg (along with oxymetholone)
• Mechanism: AR activation in kidney peritubular cells → EPO gene transcription; direct bone marrow BFU-E/CFU-E stimulation
• Clinical evidence: aplastic anemia partial response rates ~50% at 20–30 mg/day

Comparison with oxymetholone:

• At equivalent doses, erythropoietic effects are comparable
• Fluoxymesterone preferred in some clinical settings due to shorter t½ (easier dose titration) and different side effect profile (virilization without the extreme water retention of oxymetholone)

Hepatotoxicity Profile#

Expected profile (C17α-alkylated):

• Same mechanism as other C17α-alkylated androgens: BSEP inhibition → cholestasis; CYP reactive metabolites → oxidative hepatotoxicity
• Fluoxymesterone: significant hepatotoxicity risk; ALT/AST elevation common at therapeutic doses

Unique aspects:

• 9α-Fluoro: may generate fluoride ion as a metabolite during CYP metabolism → potential contribution to hepatotoxicity (fluoride is mildly toxic at high concentrations)
• Long-term use: peliosis hepatis reported; HCC association in long-term aplastic anemia patients

Clinical monitoring: ALT, AST, GGT, bilirubin every 4–6 weeks in any research protocol.

Research Protocols#

Extreme androgen AR occupancy study: dose-response in castrated rats#

AR vs. GR contribution to aggression: factorial design#

Key References#

1. Kochakian CD. (1976). "Definition of androgens and protein anabolic steroids." Pharmacology and Therapeutics, 1(2):149–177.

2. Moehlenkamp JD & Thomas JA. (1991). "Glucocorticoid and androgen receptor interactions in the prostate cell line." Molecular Endocrinology, 5(10):1442–1450.

3. Hartgens F & Kuipers H. (2004). "Effects of androgenic-anabolic steroids in athletes." Sports Medicine, 34(8):513–554.

Research Use Only: Fluoxymesterone is sold exclusively for in-vitro research and laboratory use. Not for unsupervised use. JuicedPharma does not provide medical advice.

Published by JuicedPharma Research Team · September 2026 · Category: Research Protocols & Science